SCHEMBL1853042

SCHEMBL1853042

COc1ccc2c(c1)Nc1ccccc1S2.O=C(Cl)Cl

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOX1 Q9Y5S8 12/20 0.83
▸ GAA P10253 6/20 0.68
▸ MAPT P10636 6/20 0.68
▸ MEN1 O00255 5/20 0.68
▸ KMT2A Q03164 5/20 0.68
▸ TDP1 Q9NUW8 3/20 0.68
▸ MAPK1 P28482 2/20 0.68
▸ LMNA P02545 2/20 0.68
▸ HTT P42858 2/20 0.68
▸ SMN1; SMN2 Q16637 2/20 0.68
▸ L3MBTL1 Q9Y468 1/20 0.68
▸ SNCA P37840 5/20 0.57
▸ ALOX15 P16050 3/20 0.57
▸ CYBB P04839 2/20 0.57
▸ NOX3 Q9HBY0 2/20 0.57
▸ NOX4 Q9NPH5 2/20 0.57
▸ APP P05067 1/20 0.57
▸ BCHE P06276 2/20 0.53
▸ ACHE P22303 2/20 0.53
▸ NPC1 O15118 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenothiazine SCHEMBL9074312 0.91 NOX1 (1.00) NOX1GAAMAPTMEN1KMT2A
SCHEMBL239600 0.91 NOX1 (1.00) NOX1GAAMAPTMEN1KMT2A
Benzene SCHEMBL29242182 0.90 NOX1 (0.97) NOX1GAAMAPTMEN1KMT2A
SCHEMBL4080414 0.82 NOX1 (1.00) NOX1GAAMAPTMEN1KMT2A
Phenothiazine SCHEMBL1509832 0.81 NOX1 (0.74) NOX1GAAMAPTMEN1KMT2A
SCHEMBL1856709 0.81 NOX1 (0.61) NOX1GAAMAPTMEN1KMT2A
SCHEMBL1509893 0.79 NOX1 (0.84) NOX1GAAMAPTMEN1KMT2A
SCHEMBL11580137 0.78 NOX1 (0.69) NOX1GAAMAPTMEN1KMT2A
Phenothiazine SCHEMBL6899934 0.77 NOX1 (0.69) NOX1GAAMAPTMEN1KMT2A
SCHEMBL3175562 0.77 NOX1 (0.68) NOX1GAAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1317454-B1 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMA (US) 2011-05-25 — — EP disclosed
US-6800619-B2 UREA HETEROCYCLICCARBONYL-SUBSTITUTED ASPARTIC OR GLUTAMIC ACID DERIVATIVES VERTEX PHARMACEUTICALS INCORPORATED 2004-10-05 — — US disclosed
EP-1317454-A2 CASPASE INHIBITORS AND USES THEREOF Vertex Pharmaceuticals Incorporated (US) 2003-06-11 — — EP disclosed
US-20020058630-A1 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2002-05-16 — — US disclosed
WO-2002022611-A2 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058630-A1 Caspase inhibitors and uses thereof CASP2, CASP3, CASP7 NOX1 2272/4885GAA 2738/4885MAPT 4537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback